CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners.
As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
i
This Document Has Been Replaced By: Interim clinical considerations for use of JYNNEOS and ACAM2000 vaccines during the 2022 U.S. monkeypox outbreak : JYNNEOS vaccine
Superseded
This Document Has Been Replaced By: Interim clinical considerations for use of JYNNEOS and ACAM2000 vaccines during the 2022 U.S. monkeypox outbreak : JYNNEOS vaccine
Interim clinical considerations for use of JYNNEOS and ACAM2000 vaccines during the 2022 U.S. monkeypox outbreak : JYNNEOS vaccine
-
August 10, 2022
[PDF-2.02 MB]
Details:
-
Corporate Authors:
-
Description:supersedes: cdc:120086
CDC recommends that vaccination with JYNNEOS can be considered for people determined to be at high risk for infection to prevent monkeypox disease.
Vaccination Schedule: JYNNEOS vaccine is licensed as a series of two doses administered 28 days (4 weeks) apart.
The standard regimen involves a subcutaneous (Subcut) route of administration with an injection volume of 0.5mL. The standard regimen is the FDA-approved dosing regimen. Since August 9, 2022, the standard regimen has been authorized for people aged <18 years under an Emergency Use Authorization.
-
Content Notes:Interim Guidance -- Duration of Immunity -- Dosing Intervals -- Evidence Quality -- Administration -- Interchangeability of dosing regimens -- Coadministration with other vaccines -- Patient Counseling -- Safety -- Reporting of adverse events -- Resources.
-
Subjects:
-
Series:
-
Document Type:
-
Name as Subject:
-
Collection(s):
-
Main Document Checksum:
-
Download URL:
-
File Type:
